A well-known Lithuanian biomedical scientist, Adas Darinskas, appeared before the Vilnius Regional Court on Monday, where a case is being examined concerning the possible large-scale production of alprazolam—the active ingredient in the anti-anxiety medication Xanax.

Darinskas, 47, is a recognized doctor of biomedical sciences working in the field of immunology and the holder of several patents. He is standing trial alongside two other individuals, Arturas Kasinskis and Vaidas Vilmantas.

According to prosecutors, the three men are suspected of acting as part of an organized group that may have produced, stored, and transported a particularly large quantity of alprazolam, allegedly with the intention of distributing it abroad, including in Ireland.

The defendants have not been found guilty, and the court is currently examining the evidence.

The case stems from a covert police operation carried out in October 2024, during which investigators discovered a high-tech laboratory believed to have been used for the possible illegal production of psychotropic substances.

Authorities reported seizing approximately 4.7 kilograms of alprazolam, as well as more than €400,000 in cash, which is being assessed as part of the investigation.

During the initial hearing, the charges were presented and the defendants gave their positions. Witness testimony is expected in future sessions as the court proceedings continue.

If the court were to establish guilt, the charges could carry significant prison sentences. Alprazolam, while legally prescribed to treat anxiety, has strong psychoactive effects and is known to carry a risk of misuse.

30.04.2026.